



Fax completed form to: (855) 840-1678
 If this is an URGENT request, please call (800) 882-4462
 (800.88.CIGNA)

Radicava (edaravone)

PHYSICIAN INFORMATION			PATIENT INFORMATION		
* Physician's Name:			*Due to privacy regulations we will not be able to respond via fax with the outcome of our review unless all asterisked (*) items on this form are completed.*		
Specialty:	* DEA, NPI or TIN:				
Office Contact Person:			* Patient Name:		
Office Phone:			* Cigna ID:		* Date of Birth:
Office Fax:			* Patient Street Address:		
Office Street Address:			City	State	Zip
City	State	Zip	Patient Phone:		
Urgency: <input type="checkbox"/> Standard <input type="checkbox"/> Urgent (In checking this box, I attest to the fact that applying the standard review time frame may seriously jeopardize the customer's life, health, or ability to regain maximum function)					
Medication requested: <input type="checkbox"/> Radicava Dose and Quantity: _____ Duration of therapy: _____ J-Code: _____ Frequency of administration: _____ ICD10: _____ Is this initial therapy or is the patient currently receiving Radicava IV or Radicava ORS? <input type="checkbox"/> Initial therapy <input type="checkbox"/> Currently receiving Radicava IV or Radicava ORS (if currently receiving) Has the prescriber confirmed that the patient continues to benefit from therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No (if no) Please provide support for continued use.					
Where will this medication be obtained? <input type="checkbox"/> Accredo Specialty Pharmacy** <input type="checkbox"/> Home Health / Home Infusion vendor <input type="checkbox"/> Hospital Outpatient <input type="checkbox"/> Physician's office stock (billing on a medical claim form) <input type="checkbox"/> Retail pharmacy **Cigna's nationally preferred specialty pharmacy <input type="checkbox"/> Other (please specify): _____					
<i>**Medication orders can be placed with Accredo via E-prescribe - Accredo (1620 Century Center Pkwy, Memphis, TN 38134-8822 NCPDP 4436920), Fax 888.302.1028, or Verbal 866.759.1557</i>					
Facility and/or doctor dispensing and administering medication: Facility Name: _____ State: _____ Tax ID#: _____ Address (City, State, Zip Code): _____					
Where will this drug be administered? <input type="checkbox"/> Patient's Home <input type="checkbox"/> Physician's Office <input type="checkbox"/> Hospital Outpatient <input type="checkbox"/> Other (please specify): _____					
NOTE: Per some Cigna plans, infusion of medication MUST occur in the least intensive, medically appropriate setting.					
Is this patient a candidate for re-direction to an alternate setting (such as alternate infusion site, physician's office, home) with assistance of a Specialty Care Options Case Manager? <input type="checkbox"/> Yes <input type="checkbox"/> No (provide medical necessity rationale): _____					
Is the requested medication for a chronic or long-term condition for which the prescription medication may be necessary for the life of the patient? <input type="checkbox"/> Yes <input type="checkbox"/> No					

Clinical Information:

*****This drug requires supportive documentation (chart notes, lab/test results, etc). Supportive documentation for all answers must be attached with this request.*****

What is the patient's diagnosis or reason for treatment?

- Amyotrophic Lateral Sclerosis (ALS)
- Aneurysmal Subarachnoid Hemorrhage
- Myocardial Infarction (MI)
- Radiation-Induced Brain Injury
- Retinal Vein Occlusion
- Sensorineural Hearing Loss
- Stroke
- Other (please specify): _____

(if initial therapy) Has your patient's diagnosis been documented as "definite" or "probable" amyotrophic lateral sclerosis (ALS) based on the application of the El Escorial or the revised Airlie House diagnostic criteria? Yes No

(if initial therapy) Does your patient retain most or all activities of daily living (defined as a score of 2 points or better on each item of the ALS Functional Rating Scale - Revised [ALSFRS-R])? Yes No

(if initial therapy) Does your patient have normal respiratory function (defined as a percent-predicted forced vital capacity (FVC) of at least 80%)? Yes No

(if initial therapy) How long has it been since the patient was diagnosed with ALS?

- 2 years or less
- over 2 years
- unknown

(if initial therapy) Has your patient received (or is your patient currently receiving) riluzole tablets; Tiglutik (riluzole oral suspension); or Exservan (riluzole oral film)? Yes No

Was this medication prescribed by, or in consultation with, a neurologist, a neuromuscular disease specialist, or a physician specializing in the treatment of Amyotrophic Lateral Sclerosis (ALS)? Yes No

Additional Information: *(including pertinent patient history, alternatives tried with date(s) taken and documented results, etc):*

Attestation: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan or insurer its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature: _____ **Date:** _____

Save Time! Submit Online at: www.covermymeds.com/main/prior-authorization-forms/cigna/ or via SureScripts in your EHR.

Our standard response time for prescription drug coverage requests is 5 business days. If your request is urgent, it is important that you call us to expedite the request. View our Prescription Drug List and Coverage Policies online at cigna.com.

v081524

“Cigna” is a registered service mark, and the “Tree of Life” logo is a service mark, of Cigna Intellectual Property, Inc., licensed for use by Cigna Corporation and its operating subsidiaries. All products and services are provided by or through such operating subsidiaries and not by Cigna Corporation. Such operating subsidiaries include, for example, Cigna Health and Life Insurance Company and Cigna Health Management, Inc. Address: Cigna Pharmacy Services, PO Box 42005, Phoenix AZ 85080-2005